Neurocrine Biosciences
NBIX
NBIX
640 hedge funds and large institutions have $13.6B invested in Neurocrine Biosciences in 2025 Q3 according to their latest regulatory filings, with 120 funds opening new positions, 218 increasing their positions, 219 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
2% less ownership
Funds ownership: 99.86% → 97.86% (-2%)
33% less funds holding in top 10
Funds holding in top 10: 15 → 10 (-5)
51% less call options, than puts
Call options by funds: $33.1M | Put options by funds: $67.7M
Holders
640
Holding in Top 10
10
Calls
$33.1M
Puts
$67.7M
Top Buyers
| 1 | +$177M | |
| 2 | +$65.8M | |
| 3 | +$64.3M | |
| 4 |
Two Sigma Investments
New York
|
+$48.8M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$40.2M |
Top Sellers
| 1 | -$176M | |
| 2 | -$87.4M | |
| 3 | -$43M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$42.9M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$39.3M |